Figure 4
From: RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
Diagnostic performance and treatment monitoring in South American cohorts. (a-b) ROC curve depicting diagnostic performance of RISK6 for discriminating between (a) culture-positive active TB cases (n = 48) and QuantiFERON-negative controls (n = 47), or between (b) culture-positive active TB cases (n = 48) and QuantiFERON-positive controls (n = 49) from the Peru Cohort. Shaded areas depict the 95% CI. The boxes in the top left corner represent the optimal (solid line) and minimum (dotted line) criteria set out in the target product profile for a screening/triage test for TB. (c) ROC curve depicting diagnostic performance of RISK6 for discriminating between culture-positive active TB cases, sampled prior to treatment initiation (baseline, n = 51), and controls (n = 99) from the RePORT-Brazil Cohort. (d) Comparison of RISK6 signature scores in TB cases at baseline, week 8 after treatment initiation and after treatment completion (Post Rx). Also shown are the RISK6 signature scores in healthy controls from Brazil. Horizontal lines depict medians, the boxes the IQR and the whiskers the range. Violin plots depict the density of data points. The p-value, computed by Mann-Whitney U test, compares RISK6 signature scores after treatment completion with those in controls. (e) ROC curves depicting performance of RISK6 for discriminating between healthy control samples and samples collected from TB cases before treatment initiation (baseline), at week 8 after treatment initiation, or completion of TB treatment (Post Rx). (f) ROC curves depicting performance of RISK6 for discriminating between baseline samples from TB cases and samples collected 8 weeks after treatment initiation, or upon completion of TB treatment (Post Rx).
